ELICIO THERAPEUTICS INC (ELTX) Fundamental Analysis & Valuation

NASDAQ:ELTX • US28657F1030

Current stock price

10.44 USD
-0.38 (-3.51%)
Last:

This ELTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ELTX Profitability Analysis

1.1 Basic Checks

  • ELTX had negative earnings in the past year.
  • ELTX had a negative operating cash flow in the past year.
  • In the past 5 years ELTX always reported negative net income.
  • In the past 5 years ELTX always reported negative operating cash flow.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • ELTX has a worse Return On Assets (-153.01%) than 84.53% of its industry peers.
  • The Return On Equity of ELTX (-2418.77%) is worse than 82.20% of its industry peers.
Industry RankSector Rank
ROA -153.01%
ROE -2418.77%
ROIC N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ELTX Health Analysis

2.1 Basic Checks

  • ELTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ELTX has been increased compared to 5 years ago.
  • Compared to 1 year ago, ELTX has an improved debt to assets ratio.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • ELTX has an Altman-Z score of -12.18. This is a bad value and indicates that ELTX is not financially healthy and even has some risk of bankruptcy.
  • ELTX's Altman-Z score of -12.18 is on the low side compared to the rest of the industry. ELTX is outperformed by 76.79% of its industry peers.
  • A Debt/Equity ratio of 5.75 is on the high side and indicates that ELTX has dependencies on debt financing.
  • ELTX has a worse Debt to Equity ratio (5.75) than 81.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.75
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACCN/A
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • ELTX has a Current Ratio of 2.38. This indicates that ELTX is financially healthy and has no problem in meeting its short term obligations.
  • ELTX has a Current ratio of 2.38. This is in the lower half of the industry: ELTX underperforms 72.15% of its industry peers.
  • A Quick Ratio of 2.38 indicates that ELTX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.38, ELTX is doing worse than 69.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ELTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 38.57% over the past year.
EPS 1Y (TTM)38.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.5%
EPS Next 2Y20.27%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. ELTX Valuation Analysis

4.1 Price/Earnings Ratio

  • ELTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ELTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

  • ELTX's earnings are expected to grow with 12.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.27%
EPS Next 3Y12.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELTX Dividend Analysis

5.1 Amount

  • No dividends for ELTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELTX Fundamentals: All Metrics, Ratios and Statistics

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (3/27/2026, 8:13:42 PM)

10.44

-0.38 (-3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners12.65%
Inst Owner Change7.17%
Ins Owners2.33%
Ins Owner Change35.77%
Market Cap192.10M
Revenue(TTM)N/A
Net Income(TTM)-39.57M
Analysts82.5
Price Target17.85 (70.98%)
Short Float %11.48%
Short Ratio9.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.05%
Min EPS beat(2)-6.95%
Max EPS beat(2)0.86%
EPS beat(4)2
Avg EPS beat(4)-0.83%
Min EPS beat(4)-6.95%
Max EPS beat(4)5.54%
EPS beat(8)3
Avg EPS beat(8)-9.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.9%
PT rev (3m)12.9%
EPS NQ rev (1m)-16.67%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 117.42
P/tB 117.42
EV/EBITDA N/A
EPS(TTM)-2.58
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -153.01%
ROE -2418.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 5.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -12.18
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.79%
Cap/Depr(5y)101.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
EPS Next Y40.5%
EPS Next 2Y20.27%
EPS Next 3Y12.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.38%
OCF growth 3YN/A
OCF growth 5YN/A

ELICIO THERAPEUTICS INC / ELTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ELICIO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELTX.


Can you provide the valuation status for ELICIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ELICIO THERAPEUTICS INC (ELTX). This can be considered as Overvalued.


Can you provide the profitability details for ELICIO THERAPEUTICS INC?

ELICIO THERAPEUTICS INC (ELTX) has a profitability rating of 0 / 10.